Overview

Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects with Schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Quetiapine Fumarate